Sihuan Pharmaceutical
Sihuan Pharmaceutical is a Chinese pharmaceutical manufacturer with headquarters in Beijing and branch office in Haikou, Hainan Province.[1] The main company in the group is the holding company Sihuan Pharmaceutical Holdings Group Ltd, which is listed on the Hong Kong stock market.
Sihuan Pharmaceutical is collaborating with the Academy of Military Medical Science in the development of the drug JK-05, intended for the treatment of Ebola virus disease.[1] The company has been challenged by Fujifilm Holdings Corporation, which has stated that JK-05 infringes its patent rights regarding Avigan.[2]
References
- ^ a b Patti Waldmeir and Lucy Hornby (9 October 2014). "Chinese company develops Ebola treatment". Financial Times. Retrieved 4 January 2015.
- ^ Nakanishi, Azusa (11 December 2014). "Copycats put squeeze on Japanese drugmakers". Chicago Tribune. Retrieved 4 January 2015.
External links
- http://www.sihuanpharm.com/
- v
- t
- e
- CanSino Biologics
- CSPC Zhongrun
- China Nepstar
- Fosun Pharmaceutical
- Guangzhou Pharmaceuticals
- Guangyuyuan
- Guizhentang Pharmaceutical Company
- Harbin Pharmaceutical Group
- Hebei Yuxing Bio-Engineering Co. Ltd
- Huadong Medicine
- Jilin Aodong Medicine
- Lijun International Pharmaceutical (Holding) Co. Ltd.
- Kunming Pharmaceutical Corporation
- Nanjing Ange Pharmaceutical
- North China Pharmaceutical Group
- Salubris Pharmaceuticals
- Shanghai Pharmaceuticals Holding Co., Ltd.
- Shenzhen Kangtai Biological Products
- Shijiazhuang Pharma Group
- Sihuan Pharmaceutical
- Simcere Pharmaceutical
- China National Pharmaceutical Group
- Sinovac Biotech
- Tasly
- Tong Ren Tang
- Xiangxue Pharmaceutical
- Yangtze River Pharmaceutical Group
- Yunnan Baiyao Group
- WuXi AppTec
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e
This Chinese corporation or company article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e